HDAC Inhibitors are Promising Targets in Drug Development
Since the beginning of the year a significant amount of research data has been reported on histone deacetylases (HDACs), the cellular enzymes whose functions include turning gene expression off and on. They are considered to be among the most promising targets in drug development for cancer therapy. New HDAC inhibitors are emerging and are actively being tested in the clinic.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST